JERUSALEM, Sept. 25, 2018 /PRNewswire/ -- Intec
Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today
announces that three posters in support of the Company's Phase 3
clinical development program for the Accordion Pill™
Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming
International Congress of Parkinson's and Movement Disorder Society
(MDS 2018) being held from October 5-9,
2018 in Hong Kong.
"We are particularly pleased to have several posters at this
important medical meeting discussing our Phase 3 clinical
development program for AP-CD/LD as a potential best-in-class
levodopa therapy for advanced Parkinson's disease patients," stated
Jeffrey A. Meckler, Vice Chairman
and Chief Executive Officer of Intec Pharma. "We believe these
posters will enhance visibility for our late-stage program among an
audience of scientists, clinicians and industry experts who
specialize in Parkinson's disease management."
The following posters will be presented during MDS 2018:
Title:
|
Design of a Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa
for Parkinson's Disease (PD) Patients Experiencing Motor
Fluctuations
|
Poster
Session:
|
Parkinson's Disease:
Clinical Trials, Pharmacology and Treatment
|
Poster
Number:
|
349
|
Presentation
Date:
|
Saturday,
October 6, 2018
|
Presentation
time:
|
1:45 – 3:15 pm (local
time)
|
Location:
|
Hall 3FG
|
Presenter:
|
R. Michael Gendreau,
M.D., Ph.D.,
Chief Medical Officer
of Intec Pharma
|
|
|
Title:
|
Gastric Retention of the Accordion Pill™: Results
from MRI Studies
with Parkinson's Disease Patients and Healthy Volunteers
|
Poster
Session:
|
Parkinson's Disease:
Clinical Trials, Pharmacology and Treatment
|
Poster
Number:
|
253
|
Presentation
Date:
|
Saturday, October 6,
2018
|
Presentation
time:
|
1:45 – 3:15 pm (local
time)
|
Location:
|
Hall 3FG
|
Presenter:
|
Nadav Navon,
Ph.D.,
Chief Operating
Officer of Intec Pharma
|
|
|
Title:
|
Design of a Pharmacokinetics Study with MultipleDoses of Accordion Pill™
Carbidopa/Levodopa inPatients with Parkinson's Disease
|
Poster
Session:
|
Parkinson's Disease:
Clinical Trials, Pharmacology and Treatment
|
Poster
Number:
|
266
|
Presentation
Date:
|
Saturday, October 6,
2018
|
Presentation
time:
|
1:45 – 3:15 pm (local
time)
|
Location:
|
Hall 3FG
|
Presenter:
|
C. Warren Olanow,
M.D., FRCP (hon)
Professor
Emeritus
Mount Sinai School of
Medicine
|
About Intec Pharma Ltd.
Intec Pharma is a
clinical-stage biopharmaceutical company focused on developing
drugs based on its proprietary Accordion Pill platform technology.
The Company's Accordion Pill is an oral drug delivery system that
is designed to improve the efficacy and safety of existing drugs
and drugs in development by utilizing an efficient gastric
retention and specific release mechanism. The Company's product
pipeline includes two product candidates in clinical trial stages:
Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is in
late-stage Phase 3 development for the treatment of Parkinson's
disease symptoms in advanced Parkinson's disease patients, and
AP-cannabinoids, an Accordion Pill to deliver either or both of the
primary cannabinoids contained in Cannabis sativa, cannabidiol
(CBD) and tetrahydrocannabinol (THC) for various indications
including low back neuropathic pain and fibromyalgia.
For more information, visit www.intecpharma.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward looking
statements about our expectations, beliefs and intentions.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. These forward-looking statements are based on
assumptions and assessments made in light of management's
experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be
appropriate. Forward-looking statements in this press release are
made as of the date of this press release, and we undertake no duty
to update or revise any such statements, whether as a result of new
information, future events or otherwise. Forward-looking statements
are not guarantees of future performance and are subject to risks
and uncertainties, many of which are outside of our control. Many
factors could cause our actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: our limited operating history and history of operating
losses, our ability to continue as a going concern, our ability to
obtain additional financing, our ability to successfully operate
our business or execute our business plan, the timing and cost of
our clinical trials, the completion and receiving favorable results
in our clinical trials, our ability to obtain and maintain
regulatory approval of our product candidates, our ability to
protect and maintain our intellectual property and licensing
arrangements, our ability to develop, manufacture and commercialize
our product candidates, the risk of product liability claims, the
availability of reimbursement, and the influence of extensive and
costly government regulation. More detailed information about the
risks and uncertainties affecting us is contained under the heading
"Risk Factors" included in our most recent Annual Report on Form
20-F filed with the SEC on March 9,
2018, and in other filings that we have made and may make
with the Securities and Exchange Commission in the future.
Intec Pharma Investor Contact:
Anne Marie
Fields
VP-Corporate Communications & Investor Relations
+1-646-200-8808
amf@intec-us.com
View original
content:http://www.prnewswire.com/news-releases/intec-pharma-to-present-multiple-posters-at-international-congress-of-parkinsons-and-movement-disorder-society-300717925.html
SOURCE Intec Pharma Ltd.